SCHEMBL25754589

SCHEMBL25754589

COc1ccc(NC(=O)c2c(C(F)(F)F)ccnc2C)cc1S(=O)(=O)Nc1c(C)cccc1C

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.52
MEN1 O00255 4/20 0.52
LMNA P02545 3/20 0.52
GAA P10253 3/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
ALDH1A1 P00352 1/20 0.52
ALOX12 P18054 1/20 0.52
CRHBP P24387 1/20 0.52
CRHR2 Q13324 1/20 0.52
HPGD P15428 1/20 0.45
AXL P30530 2/20 0.44
MAPT P10636 4/20 0.44
POLB P06746 2/20 0.44
KDM4E B2RXH2 1/20 0.44
HTT P42858 1/20 0.44
ALPL P05186 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25754538 0.84 KMT2A (0.52) KMT2AMEN1LMNAGAASMN1; SMN2
SCHEMBL25754499 0.82 LMNA (0.48) KMT2AMEN1LMNAGAASMN1; SMN2
SCHEMBL25755378 0.81 MAPT (0.46) KMT2AMEN1LMNAGAASMN1; SMN2
SCHEMBL23846381 0.81 SCN10A (0.39) SMN1; SMN2KDM4E
SCHEMBL25754596 0.80 MEN1 (0.52) KMT2AMEN1LMNAGAASMN1; SMN2
SCHEMBL23846393 0.79 SMN1; SMN2 (0.48) KMT2AMEN1LMNAGAASMN1; SMN2
SCHEMBL25754528 0.79 LMNA (0.47) KMT2AMEN1LMNAGAASMN1; SMN2
SCHEMBL23846526 0.78 KMT2A (0.49) KMT2AMEN1LMNAGAASMN1; SMN2
SCHEMBL25755284 0.78 TRPV1 (0.49) KMT2AMEN1LMNAGAASMN1; SMN2
SCHEMBL23846665 0.77 KMT2A (0.53) KMT2AMEN1LMNAGAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-06-08 US disclosed
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF TRAP1, PINK1, TP53BP1 KMT2A 4864/4885MEN1 3902/4885LMNA 3435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.